Neutralization with an anti-Hmgb1 antibody has been shown to inhibit mechanical allodynia in neuropathic pain models when injected systemically [41,144,151,152] or peripherally [142], and in inflammatory pain models when injected peripherally [149] or intrathecally [127]; it has also been utilized to reduce mechanical sensitivity associated with models of type 2 diabetes [153], pancreatitis [154], bone cancer [155], and bladder pain [156]. Here, HMGB1 is linked to type 2 diabetes mellitus.